Modulation of the potency of promutagens and direct acting mutagens in bacteria by inhibitors of the multidrug resistance mechanism.
Multiple drug resistance (MDR) mechanisms are known to limit the effectiveness of some cancer chemotherapies, probably through enhancing P-glycoprotein-mediated drug efflux from mammalian cells. Similar mechanisms appear to act in other organisms, including bacteria, and may affect not only the toxicity but also the mutagenicity of certain chemicals. At least in some experimental situations, MDR can be overcome through concomitant treatment of the cells with various types of inhibitors. Two MDR inhibitors, verapamil, a calcium channel blocker, and trifluoperazine, a calmodulin inhibitor, were assayed for their ability to modulate the potency of nine mutagens with varying mechanisms of action in various Salmonella typhimurium his- strains. Neither verapamil nor trifluoperazine affected the direct mutagenicity of sodium dichromate and 2-methoxy-6-chloro-9[3-(2-chloroethyl)amino-propyl-amino] dihydrochloride (ICR 191) or the S9-mediated mutagenicity of benzo[a]pyrene and 2-amino-3,4-dimethyl-amidazo[4,5-f]quinoline (MeIQ). Both modulators enhanced the direct mutagenicity of doxorubicin. Moreover, trifluoperazine sharply increased the S9-mediated mutagenicity of cyclophosphamide and 2-aminofluorene, while it consistently decreased the mutagenicity of 3-amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2). The contrasting effect towards the aromatic amine 2-aminofluorene and the heterocyclic amine Trp-P-2, representative of important chemical families responsible for the bacterial mutagenicity of cigarette smoke, may explain the observed lack of influence of trifluoperazine on the mutagenicity of a cigarette smoke condensate. These observations extend the known range of chemical types whose mutagenicity can be modulated by inhibitors of MDR and suggest that there may be value in adding MDR inhibitors, especially trifluoperazine, to optimize the detection of mutagenicity by certain types of chemicals in the Salmonella/mammalian microsome mutagenicity test.
De Flora
S
S
Institute of Hygiene and Preventive Medicine, University of Genoa, Italy. sdf@unige.it
Camoirano
A
A
Cartiglia
C
C
Ferguson
L
L
D000166:Acridines / Q000633:toxicity; D000585:Aminacrine / Q000031:analogs & derivatives / Q000633:toxicity; D001564:Benzo(a)pyrene / Q000037:antagonists & inhibitors / Q000633:toxicity; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002840:Chromates / Q000037:antagonists & inhibitors / Q000633:toxicity; D003520:Cyclophosphamide / Q000037:antagonists & inhibitors / Q000633:toxicity; D018492:Dopamine Antagonists / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000037:antagonists & inhibitors / Q000633:toxicity; D018432:Drug Resistance, Multiple / Q000502:physiology*; D005449:Fluorenes / Q000037:antagonists & inhibitors / Q000633:toxicity; D007211:Indoles / Q000037:antagonists & inhibitors / Q000633:toxicity; D016296:Mutagenesis / Q000187:drug effects*; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity*; D009154:Mutation / Q000187:drug effects; D009538:Nicotine / Q000037:antagonists & inhibitors / Q000633:toxicity; D009588:Nitrogen Mustard Compounds / Q000633:toxicity; D011804:Quinolines / Q000037:antagonists & inhibitors / Q000633:toxicity; D012486:Salmonella typhimurium / Q000187:drug effects*; D014268:Trifluoperazine / Q000494:pharmacology*; D014700:Verapamil / Q000494:pharmacology*
D000166:Acridines; D002121:Calcium Channel Blockers; D002840:Chromates; D018492:Dopamine Antagonists; D005449:Fluorenes; D007211:Indoles; D009153:Mutagens; D009588:Nitrogen Mustard Compounds; D011804:Quinolines; D014268:Trifluoperazine; D001564:Benzo(a)pyrene; C041509:fluorene; D009538:Nicotine; D000585:Aminacrine; D004317:Doxorubicin; C030374:indole; D003520:Cyclophosphamide; C004294:acridine half-mustard; C016104:sodium bichromate; D014700:Verapamil; C037219:quinoline